Fidelity National Financial, Inc.·4

May 12, 4:20 PM ET

Nolan Michael Joseph 4

4 · Fidelity National Financial, Inc. · Filed May 12, 2026

Research Summary

AI-generated summary of this filing

Updated

FNF CEO Nolan Michael Joseph Receives 39,542-Share Award

What Happened Nolan Michael Joseph, CEO of Fidelity National Financial, received a grant of 39,542 restricted common shares on 2026-05-08. The shares were issued at $0.00 (award), so no cash was paid; reported value on Form 4 is $0. The award is compensation rather than an open-market purchase or sale.

Key Details

  • Transaction date: 2026-05-08; Form 4 filed: 2026-05-12 (timely filing within required two business days).
  • Transaction type/code: A (award/grant); 39,542 shares acquired at $0.00.
  • Vesting: Grant vests in three equal annual installments beginning May 8, 2027 (Footnote F1).
  • Other note: Amount adjusted to reflect shares acquired under the registrant’s Employee Stock Purchase Plan (Footnote F2).
  • Shares owned after transaction: not specified in the provided filing summary.

Context This was a restricted stock award — common executive compensation intended to align management with shareholder interests as shares vest over time. Such grants are not the same as insider purchases on the open market and do not necessarily signal an immediate trading view by the insider. The filing appears timely (transaction 5/8, Form 4 filed 5/12).

Insider Transaction Report

Form 4
Period: 2026-05-08
Nolan Michael Joseph
Chief Executive Officer
Transactions
  • Award

    Common Stock

    [F1][F2]
    2026-05-08+39,542601,672.085 total
Holdings
  • Common Stock

    (indirect: By Trust)
    14,585.324
Footnotes (2)
  • [F1]Grant of restricted common stock vesting in three equal annual installments beginning May 8, 2027.
  • [F2]Amount adjusted to reflect shares acquired under the registrant's Employee Stock Purchase Plan.
Signature
/s/ Colleen E. Haley, as attorney-in-fact|2026-05-12

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT